Durvalumab vs Ranitidine

## Durvalumab vs Ranitidine: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Ranitidine**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Ranitidine**: Competitive H2 receptor antagonist.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Ranitidine — 2-3 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Ranitidine — C13H22N4O3S.

**Molecular Weight**: Durvalumab — N/A; Ranitidine — 314.4050 g/mol.

**Type**: Durvalumab — Antibody; Ranitidine — Small molecule.